Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 372-377, July 2008

Joshua H. Petit, M.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
- Corresponding author. Tel.: +1-617-667-2345; fax: +1-617-667-4990.
Clifford Gluck, M.D.
- Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
W.S. Kiger III, Ph.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
D. Laury Henry, B.S.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Carol Karasiewicz, B.S.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
James Talcott, M.D.
- Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02214, USA
Solomon Berg, M.D.
- Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Edward Holupka, Ph.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Irving Kaplan, M.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA